EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions

Izabella Ryguła iD, Wojciech Pikiewicz, Konrad Kaminiów iD

Molecules · 2023

DOI: 10.3390/molecules28248064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2023. Verfasst von Izabella Ryguła und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Vitiligo. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the cell nucleus, thus disrupting the JAK-STAT pathway. This pathway plays a role in key cellular processes such as the immune response and cell growth. This feature is used in the treatment of patients with rheumatological, gastroenterological and hematological diseases. Recently, it has been discovered that JAK-STAT pathway inhibitors also show therapeutic potential against dermatological diseases such as atopic dermatitis, psoriasis, alopecia areata and acquired vitiligo. Studies are underway to use them in the treatment of several other dermatoses. Janus kinase inhibitors represent a promising class of drugs for the treatment of skin diseases refractory to conventional therapy. The purpose of this review is to summarize the latest knowledge on the use of JAKi in dermatological treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsVitiligoHumansJanus KinasesSignal TransductionSTAT Transcription Factors

Stichwörter der Autor:innen

JAK inhibitorsJAK-STAT pathwayJAKinibsJanus kinase inhibitorsautoimmune skin diseasesdermatologyinflammatory skin conditions

Substanzen

Janus Kinase InhibitorsJanus KinasesSTAT Transcription Factors

Autor:innen und Institutionen

  • Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
  • Department of Medical and Health Sciences, Collegium Medicum-Faculty of Medicine, WSB University, 41-300 Dąbrowa Górnicza, Poland.

ORCID-Profile: Izabella Ryguła, Konrad Kaminiów

Zitieren

APA

Ryguła, I., Pikiewicz, W., & Kaminiów, K. (2023). Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions. Molecules. https://doi.org/10.3390/molecules28248064

Vancouver

Ryguła I, Pikiewicz W, Kaminiów K. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions. Molecules. 2023. doi:10.3390/molecules28248064

BibTeX
@article{Rygua2023,
  author = {Ryguła, Izabella and Pikiewicz, Wojciech and Kaminiów, Konrad},
  title = {Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28248064}
}
Kostenlos starten →